Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
108Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.27B | $157.00M | $0.43 |
| 2024 | $9.63B | $-46.00M | $-0.13 |
| 2023 | $8.76B | $-592.00M | $-1.62 |
| 2022 | $8.12B | $-225.00M | $-0.62 |
| 2021 | $8.43B | $-948.00M | $-2.61 |
Social Signal Score
Earnings
Wed, Oct 28(in 2 months)
Consensus estimate $1.19 per share
Typical surprise -7.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$1.26 vs $0.96beat
- Wed, Apr 29$0.78 vs $0.81miss
- Wed, Feb 18$1.08 vs $1.21miss
- Wed, Oct 29$1.16 vs $1.07beat
- Wed, Jul 30$0.90 vs $0.97miss
- Wed, Apr 30$0.59 vs $0.83miss
Estimates and results for BHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.62
- Implied price
- $9.95
- Return from $6.51
- 8.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.95 — -24.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 14 | 16 | 18 | 20 |
|---|---|---|---|---|---|
| -2.0% | -6.7% | -3.8% | -1.2% | 1.1% | 3.3% |
| 3.0% | -2.0% | 1.1% | 3.8% | 6.3% | 8.6% |
| 8.0% | 2.8% | 6.0% | 8.9% | 11.5% | 13.8% |
| 13.0% | 7.5% | 10.9% | 13.9% | 16.6% | 19.1% |
| 18.0% | 12.3% | 15.8% | 18.9% | 21.8% | 24.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (2)
- Newsseekingalpha.com·2d ago·Neutral
Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.
View source ↗ - Newszacks.com·4d ago·Positive
Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗